GEn1E Lifesciences Inc.
Clinical-stage, Phase 2 company accelerating novel Precision Therapies for I&I and Rare Diseases using AI
18 employees · est. 2019 · Palo Alto, United States
Nuvamid
A clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare diseases
4 employees · est. 2019 · Nyon, Switzerland
GEn1E Lifesciences Inc. is the larger of the two.
Side-by-Side Comparison
| Metric | GEn1E Lifesciences Inc. | Nuvamid |
|---|---|---|
| Founded | ||
| Founded | 2019 | 2019 |
| Headquarters | ||
| Headquarters | Palo Alto, United States | Nyon, Switzerland |
| Employees | ||
| Employees | 18 larger | 4 |
| Industry | ||
| Industry | AI, Biotechnology, Health Care | Health Care, Manufacturing, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Series A | Not tracked yet |
| Total Funding | ||
| Total Funding | $17.03M | Not tracked yet |
| Funding Rounds | ||
| Funding Rounds | 6 | Not tracked yet |
| Services | ||
| Services | Drug development from discovery to clinical trials, Development of novel therapeutics for inflammatory and rare diseases, Utilization of advanced AI platform for drug development | Research and development of nucleotide-based therapies, Clinical stage trials for rare blood diseases, Collaboration with academic and research institutions |
| Target Customers | ||
| Target Customers | Patients with inflammatory diseases, Patients with rare diseases, Healthcare providers, Pharmaceutical industry stakeholders | Patients with rare blood diseases, Healthcare providers specializing in rare diseases, Pharmaceutical and biotech partners |
| Taxonomy | ||
| Taxonomy | AI Platform, Drug Development, Immunomodulatory Therapies, Rare Diseases, Inflammatory Diseases, Multi-target Company, Clinical-stage, Novel Therapeutics, YCombinator, Stanford-StartX, Palo Alto, Seed Capital, IND, Biotech Industry | Clinical Stage Biotech, Nucleotide Therapeutics, Rare Diseases, Endogenous Molecules, Breakthrough Therapeutics, Rare Blood Diseases, Blood Cell Disorders, NUV01, Phase 2 Clinical Trials, NAD Metabolism, NAD Metabolism Modulators, Preclinical Data, Immune Disorders, Research Collaborations, Biopharmaceutical Development |
| Website | ||
| Website | gen1e.com | nuvamid.com |
About GEn1E Lifesciences Inc.
GEn1E Lifesciences Inc. is a clinical-stage company headquartered in the United States that is pioneering the use of AI in drug development, particularly targeting rare and inflammatory diseases. Founded in 2018, GEn1E leverages its proprietary AI platform to expedite the creation of immunomodulator...
About Nuvamid
Nuvamid, founded in 2019 and headquartered in Switzerland, is a clinical stage biotech with a focus on the research and utilization of nucleotides as therapeutics for rare diseases. Known for their slogan, "A clinical stage biotech focused on the research and use of nucleotides, as therapeutics for...
We will tell you when either one moves
BounceWatch watches GEn1E Lifesciences Inc. and Nuvamid for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at GEn1E Lifesciences Inc... and Nuvamid — by email.
Frequently Asked Questions
Compare GEn1E Lifesciences Inc. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at GEn1E Lifesciences Inc. on 12 Sep 2024, and Nuvamid on 4 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
